Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vbi Vaccines Inc CS
(NQ:
VBIV
)
0.0653
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vbi Vaccines Inc CS
< Previous
1
2
3
4
5
6
7
Next >
VBI Vaccines Reveals Updated Overall Survival Data From Brain Cancer Vaccine Trial
December 02, 2021
VBI Vaccines Inc (NASDAQ: VBIV) has presented updated 12-month and 18-month overall survival (OS) data from the Phase 2a study of VBI-1901, the Company's...
Via
Benzinga
VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021
December 01, 2021
From
VBI Vaccines Inc.
Via
Business Wire
BYSI Stock Alert: Bad News From the FDA Has BeyondSpring Tanking Today
December 01, 2021
BeyondSpring is falling hard after the FDA turned down a once-promising drug candidate. Here's why you shouldn't write off BYSI stock.
Via
InvestorPlace
Exposures
Product Safety
Nubank IPO: 12 Things for Potential Investors to Know About the Buffett-Backed Brazilian Fintech
December 01, 2021
Nubank is in the news today as investors discuss new details from the fintech company's filing for an initial public offering (IPO).
Via
InvestorPlace
Topics
Initial Public Offering
Exposures
Securities Market
OP Stock: 13 Things for OceanPal Investors to Know About the Diana Shipping Spinoff as Shares Soar
December 01, 2021
OceanPal (OP) stock is riding higher Wednesday on the wave of its public debut yesterday after a spinoff from Diana Shipping (DSX)!
Via
InvestorPlace
VBIV Stock Is Shooting Higher on Big FDA Vaccine Approval News
December 01, 2021
VBI Vaccines just got the green light from the FDA for its new Hepatitis B vaccine. VBIV stock is reacting well so far today.
Via
InvestorPlace
Exposures
Product Safety
FDA Approves VBI Vaccines' 3-Antigen Hepatitis B Vaccine
December 01, 2021
The FDA has approved VBI Vaccines Inc's (NASDAQ: VBIV) PreHevbrio [Hepatitis B Vaccine (Recombinant)] to prevent the infection caused by all known subtypes of...
Via
Benzinga
Exposures
Product Safety
VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults
December 01, 2021
From
VBI Vaccines Inc.
Via
Business Wire
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
November 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More
November 28, 2021
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week.
Via
Talk Markets
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
November 28, 2021
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses...
Via
Benzinga
Exposures
COVID-19
Product Safety
VBI Vaccines to Participate in Jefferies London Healthcare Conference
November 16, 2021
From
VBI Vaccines Inc.
Via
Business Wire
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 08, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
November 02, 2021
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...
Via
Benzinga
VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021
November 01, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open
October 13, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines to Participate in Upcoming Investor Conferences
October 04, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern
September 29, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 02, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Appoints Linda Bain to Board of Directors
July 07, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine
July 01, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Why Shares of VBI Vaccines Soared, and Then Fell 7%, on Tuesday
June 29, 2021
Investors almost seemed ready to take profits once shares hit their highest level since February.
Via
The Motley Fool
Exposures
COVID-19
VBI Vaccines Stock Is Trading Higher On Encouraging Data From COVID-19 Vaccine Candidate Trial
June 29, 2021
VBI Vaccines Inc (NASDAQ: VBIV) has announced positive Phase 1 data from its Phase 1/2 trial evaluating its enveloped virus-like particle (eVLP) COVID-19 vaccine...
Via
Benzinga
Exposures
COVID-19
VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19
June 29, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
June 23, 2021
From
Brii Biosciences
Via
Business Wire
VBI Vaccines to Present at Upcoming Scientific Conferences
June 17, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Results of Annual General Meeting
June 09, 2021
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021
June 09, 2021
From
VBI Vaccines Inc.
Via
Business Wire
Why Agenus Stock Is Jumping Today
June 08, 2021
There was some positive news, but it probably wasn't a huge catalyst for the stock.
Via
The Motley Fool
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.